Antifungals targeted to the cell wall

Area of Science:

• Mycology
• Pharmacology
• Immunology

Background:

• Serious fungal infections pose a significant threat to immunocompromised individuals.
• Current antifungal treatments like amphotericin and azoles have limitations, including toxicity and reduced efficacy.
• There is an unmet medical need for safer and more effective antifungal therapies.

Purpose of the Study:

• To review the development of novel antifungal agents targeting the fungal cell wall.
• To highlight the mechanisms of action and potential benefits of these new antifungals.

Main Methods:

• Review of existing literature on antifungal drug development.
• Analysis of compounds targeting fungal cell wall synthesis, specifically chitin synthase and alpha-1,3-glucan synthase.
• Evaluation of clinical development status of selected antifungal agents.

Main Results:

• Two classes of cell wall-acting antifungals are in clinical development: nikkomycin Z (chitin synthase inhibitor) and echinocandin/pneumocandin derivatives (alpha-1,3-glucan synthase inhibitors).
• These agents offer inherent selectivity and fungicidal activity.
• They represent promising alternatives to current antifungals with improved safety and efficacy profiles.

Conclusions:

• Novel antifungal drugs targeting the fungal cell wall are advancing in clinical development.
• These new agents hold promise for improved treatment of serious fungal infections in vulnerable patient populations.
• Continued research and development in this area are crucial to address the growing challenge of antifungal resistance and treatment limitations.